Home » Stocks » ONCR

Oncorus, Inc. (ONCR)

Stock Price: $25.85 USD -0.35 (-1.34%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 592.54M
Revenue (ttm) n/a
Net Income (ttm) -43.35M
Shares Out 21.78M
EPS (ttm) -1.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $25.85
Previous Close $26.20
Change ($) -0.35
Change (%) -1.34%
Day's Open 26.09
Day's Range 25.60 - 26.76
Day's Volume 31,466
52-Week Range 15.00 - 35.55


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

-- Preclinical findings show that ONCR-177's systemic antitumor immunity is driven by its  five complementary immunomodulatory transgene payloads and retention of γ 34.5 -- -- Complete and dur...

GlobeNewsWire - 2 weeks ago

-- 88,000 square foot state-of-the-art facility will support Oncorus' advancing, multi-product  pipeline of intratumorally and intravenously administered viral immunotherapies –

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announ...

GlobeNewsWire - 2 months ago

-- Received $98.4 million in aggregate gross proceeds in October from initial public offering -- -- Initiated Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the tr...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to tran...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc., a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes ...

Seeking Alpha - 3 months ago

Oncorus Finalizes $87 Million U.S. IPO Effort

Market Watch - 3 months ago

Biotech Oncorus Inc. set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $14 to $16 each.

About ONCR

Oncorus, a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supp... [Read more...]

IPO Date
Oct 2, 2020
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Oncorus stock is "Strong Buy." The 12-month stock price forecast is 38.67, which is an increase of 49.59% from the latest price.

Price Target
(49.59% upside)
Analyst Consensus: Strong Buy